Terms: = Leukemia AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Clinical Outcome
11 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. CPT1B, a metabolic molecule, is also an independent risk factor in CN-AML.
Ling Q; Mao S; Pan J; Wei W; Qian Y; Li F; Huang S; Ye W; Lin X; Huang J; Wang J; Jin J
Cancer Biomark; 2023; 37(3):133-145. PubMed ID: 36938722
[TBL] [Abstract] [Full Text] [Related]
3. [clinical outcome of allogeneic hematopoietic stem cell transplantation in the treatment of 9 myeloid leukemia patients with granulocytic sarcoma].
Liang LJ; Zhou J; Zhang YL; Fu YW; Zu YL; Yu FK; Lin QD; Han LJ; Wang Q; Fang BJ; Wei XD; Song YP
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):216-219. PubMed ID: 29518868
[TBL] [Abstract] [Full Text] [Related]
4. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.
Doki N; Ohashi K; Oshikawa G; Kobayashi T; Kakihana K; Sakamaki H
Pathol Oncol Res; 2014 Jan; 20(1):61-6. PubMed ID: 23821455
[TBL] [Abstract] [Full Text] [Related]
6. [clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Pei RZ; Li SY; Zhang PS; Ma JX; Liu XH; Du XH; Chen D; Sha KY; Chen LG; Cao JJ; Zhuang XX; Wu JY; Lin L; Fan Z; Ye PP; Tang SH; Zhang BB; Shi XW
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):144-8. PubMed ID: 23611222
[TBL] [Abstract] [Full Text] [Related]
7. Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre.
Bilmon IA; Kwan J; Gottlieb D; Kerridge I; McGurgan M; Huang G; George B; Hertzberg M; Bradstock KF
Intern Med J; 2013 Feb; 43(2):191-6. PubMed ID: 22646924
[TBL] [Abstract] [Full Text] [Related]
8. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
Griffiths EA; Gore SD; Hooker C; McDevitt MA; Karp JE; Smith BD; Mohammad HP; Ye Y; Herman JG; Carraway HE
Leuk Lymphoma; 2010 Sep; 51(9):1711-9. PubMed ID: 20795789
[TBL] [Abstract] [Full Text] [Related]
9. Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial results.
Aschoff P; Häntschel M; Oksüz M; Werner MK; Lichy M; Vogel W; Pfannenberg C
Nuklearmedizin; 2009; 48(5):185-91. PubMed ID: 19710955
[TBL] [Abstract] [Full Text] [Related]
10. Granulocytic sarcoma: 32 cases and review of the literature.
Paydas S; Zorludemir S; Ergin M
Leuk Lymphoma; 2006 Dec; 47(12):2527-41. PubMed ID: 17169797
[TBL] [Abstract] [Full Text] [Related]
11. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract] [Full Text] [Related]
